Fairvalue-Calculator Fairvalue-Calculator
EN DE

HYUNDAI BIOLAND Co (052260) Fair Value & Analysis

Consumer Non-Cyclicals · KR · Market cap 112B KRW

Price3,400 KRW
Fair Value353.67 KRW
Upside-89.6%
Quality95/100
Evidence: High Range 265.25 KRW – 442.09 KRW

Fair value as of: Jun 25, 2026

Analysis

HYUNDAI BIOLAND Co (052260) currently trades at 3,400 KRW, while our model-based Fair Value estimate is 353.67 KRW — implying the stock looks roughly 89.6% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Non-Cyclicals sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDAI BIOLAND Co.,Ltd in October 2020. HYUNDAI BIOLAND Co.,Ltd was incorporated in 1995 and is based in Cheongju, South Korea.

Open the full interactive analysis →

Similar stocks

NeoPharm CO., LTD. (092730) +356% Csa Cosmic Co (083660) +33% AUX (AUX) -70% Sierra Madre Gold and Silver Ltd (SM) +37% FB (FB) -19% JGS (JGS) -23%

Frequently asked questions

Is HYUNDAI BIOLAND Co (052260) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 353.67 KRW versus a price of 3,400 KRW — about −90% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 052260?
Our 21-model fair value for HYUNDAI BIOLAND Co is 353.67 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 3,400 KRW.
What is the quality score of 052260?
HYUNDAI BIOLAND Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.